Last reviewed · How we verify
NCT06585176
Epidemiological Studies and Risk Factor Analysis of GERD in Xiamen City
trial testing No intervention in Gastroesophageal Reflux Disease in 1,625 participants. Completed in 31 October 2025.
31 October 2025
Quick facts
| Lead sponsor | Zhongshan Hospital (Xiamen), Fudan University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 1,625 |
| Start date | 1 August 2024 |
| Primary completion | 31 October 2025 |
| Estimated completion | 31 October 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- No intervention
Conditions studied
- Gastroesophageal Reflux Disease — all drugs for Gastroesophageal Reflux Disease →
- Epidemiology — all drugs for Epidemiology →
- Risk Factors — all drugs for Risk Factors →
Sponsor
Zhongshan Hospital (Xiamen), Fudan University
Who can join
Adults 16 to 75, any sex, with Gastroesophageal Reflux Disease or Epidemiology. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Gastroesophageal Reflux Disease (GERD) is a condition characterized by the reflux of gastric and duodenal contents into the esophagus, primarily manifested by symptoms such as acid regurgitation and heartburn. GERD significantly affects patients' daily lives and health-related quality of life. Prolonged gastroesophageal reflux can lead to repeated irritation of the esophageal mucosa by gastric acid and acidic gastric contents, resulting in the replacement of normal squamous epithelium in the lower esophagus with metaplastic columnar epithelium. This pathological change, known as Barrett's Esophagus (BE), is considered a precancerous lesion for esophageal adenocarcinoma.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06585176
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of No intervention
Trials testing the same drug.
- NCT06643052 — Cahnge in Management of Suspected Early Onset Neonetal Sepsis After Assimilation of Early Onset Sepsis Calculator · not yet recruiting
- NCT07540611 — Gonadotropin Therapy in Idiopathic Hypogonadal Non-Obstructive · NA · not yet recruiting
- NCT07291778 — Doppler Evaluation for Congestive Acute Kidney Injury in Critical Illness · NA · not yet recruiting
- NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
- NCT07515365 — Colitis Patterns in Patients With Lower GI Symptoms · not yet recruiting
Other recruiting trials for Gastroesophageal Reflux Disease
Currently open trials in the same condition.
- NCT06783751 — Mechanistic and Clinical Outcomes of a Surgical Innovation Aimed at Minimizing GERD Associated With VSG (INNOVATE-VSG) · NA · recruiting
- NCT06348420 — Anti-reflux Mucosal Valvuloplasty Versus PPIs for GERD Treatment · NA · recruiting
- NCT06991348 — Clinical Trial for the Comparative Evaluation of Acid Suppression and Symptom Management of Gastroesophageal Reflux Dise · Phase 4 · recruiting
- NCT06732661 — Preserving the Pre-cardial Fat Pad During Sleeve Gastrectomy on Postoperative Gastroesophageal Reflux · NA · active not recruiting
- NCT05514769 — Proximal Gastrectomy Anterior Anastomosis With Pyloroplasty Versus Esophagogastric Anastomosis for Gastric Cancer · NA · recruiting
Other Zhongshan Hospital (Xiamen), Fudan University trials
Trials by the same sponsor.
- NCT06977841 — Tegoprazan-Based Therapies for H. Pylori Eradication: A Randomized Controlled Trial · NA · completed
- NCT07122284 — Gut Microbiome-Metabolome Profiling in H. Pylori-SIBO Comorbidity · completed
- NCT06292546 — The Effects of High-dose Dual Therapy With Probiotics on Gut Microbiota for Helicobacter Pylori Rescue Treatment · NA · completed
- NCT06293287 — Enoxaparin for Preventing the Radical Artery Occlusion After the Transradial Access Hepatic Arterial Infusion Chemothera · Phase 2 · unknown
- NCT05721300 — Study on Screening, Verification and Intervention of High-risk Patients With Liver Cancer · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06585176 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zhongshan Hospital (Xiamen), Fudan University
- Last refreshed: 13 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06585176.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing